(ACE) inhibitors, diuretics, and digoxin. Once the patients achieved volume control, they were considered eligible for weaning from milrinone. Phosphodiesterase inhibitors have been shown to demonstrate continued positive inotropic effects in patients on β-blockers. [6] [7] [8] Therefore we chose to initiate the β-blocker therapy before any weaning attempts, with the rationale that milrinone may ameliorate the potential worsening of heart failure. We describe our experience in titration of carvedilol in these patients compared with the usual carvedilol titration in patients never requiring intravenous inotropic support.
Methods
We conducted a retrospective review of all patients started on carvedilol at our heart failure clinic from March 1998 to June 1999 (n = 32). Baseline clinical characteristics were obtained before β-blockade in both groups. The left ventricular ejection fraction was calculated on all patients from the Mmode measurements on their most recent echocardiographic study or by a gated blood pool scan.
Patients who were initially stabilized on intermittent milrinone infusions then titrated on carvedilol were classified as group 1. Patients never requiring intermittent inotropic therCarvedilol, a nonselective β-blocker, has been shown to inhibit clinical progression of heart failure, improve cardiac function, and decrease symptoms in patients with New York Heart Association (NYHA) class I, II, and III heart failure. [1] [2] [3] The usefulness of carvedilol in patients with more advanced heart failure has been limited because of the frequent occurrence of side effects in >40% of the patients, especially on initiation of therapy. 4 There are limited retrospective data with a combination of β-blocker and oral phosphodiesterase inhibitors in patients with chronic, severe, medically refractory congestive heart failure (CHF). 5 Patients in NYHA functional class IIIb/IV CHF were referred to our clinic for treatment with intermittent milrinone therapy because of recurrent hospitalizations or decompensation. During these treatments, patients were maximized on angiotensin-converting enzyme Background Carvedilol has been shown to improve morbidity and mortality in patients with congestive heart failure (CHF). There are limited data of carvedilol use in patients on inotrope therapy. We present our experience with carvedilol titration in New York Heart Association (NYHA) class IIIb/IV patients stabilized on milrinone therapy, as a nonrandomized study with a parallel control group of patients never on inotropes. These patients achieved volume control and stabilization of their symptoms during the course of milrinone therapy.
Methods and Results
Seventeen patients in class IIIb/IV CHF (group 1) on intermittent intravenous milrinone therapy and 15 patients in class II/IIIa compensated CHF (group 2) on standard triple heart failure therapy were titrated on carvedilol. Success and adverse events during titration were compared between the 2 groups. Fifteen (88%) patients in group 1 and 14 (93%) patients in group 2 were successfully titrated on carvedilol over 8.1 ± 1.8 weeks and 6.7 ± 2.8 weeks, respectively. The target dose of carvedilol (25 or 50 mg twice daily) was achieved in 13 (87%) patients (group 1) and 14 (93%) patients (group 2). Seven (47%) patients in group 1 and 4 (28%) patients in group 2 had adverse events during carvedilol titration. Eight (53%) patients in group 1 were weaned off milrinone over a period of 8.4 weeks after carvedilol titration, whereas the rest of the patients had reduction in the frequency of infusion. Ten (63%) patients in group 1 improved by one or more functional classes.
Conclusions
Patients in NYHA class IIIb/IV who are treated with inotropic therapy can be titrated on carvedilol after reaching a stable state while on milrinone and standard oral drugs. Most of these patients can be successfully weaned off of milrinone or have decreased frequency of infusions and demonstrate improved functional status. Prospective randomized trials are required to evaluate these observations made in a limited number of patients in class IIIb and IV CHF because the combination of milrinone and β-blockers has never been adequately evaluated. (Am Heart J 2001;142:512-5.) apy were classified as group 2. Carvedilol was administered to all patients at the heart failure clinic with a usual starting dose of 3.125 mg by mouth twice daily. Carvedilol was up-titrated every 2 weeks or as tolerated to the maximum tolerated dose or a target dose of 25 mg twice daily was reached. Patients in group 2 with a dry body weight of >85 kg were titrated to 50 mg twice daily.
Group 1 patients continued to receive intermittent milrinone therapy during the β-blocker titration. A standard dose of 50 µg/kg bolus over 10 minutes followed by 0.5 µg/kg/min (or 0.375 µg/kg/min if the creatinine clearance was <30 mL/min) for 4 hours was administered to all patients. On days of β-blocker initiation or up-titration, carvedilol was administered at the start of the third hour of the infusion. Once titrated to the maximum tolerable dose of carvedilol, attempts were made to wean these patients off the milrinone therapy. The frequency of milrinone infusion was gradually decreased as tolerated.
Patients were monitored for orthostasis, hypotension, dizziness, or any adverse event for 60 minutes after the ingestion of each dose of carvedilol in the clinic. A detailed history for adverse events and examination for hypotension, orthostasis, worsening heart failure, and determination of rhythm was performed on each of the visits. Patients were also monitored closely for any adverse events, hospitalizations, and emergency department visits for CHF during the titration phase and subsequent follow-up.
The success of carvedilol titration, the maximum dose of carvedilol achieved, titration period to the maximum dose, and frequency of adverse events during the titration were compared between the 2 groups. The frequency of milrinone infusions and the functional class before and after milrinone/carvedilol administration were also assessed for group 1 patients.
Statistical analysis
All data are presented as the mean ± SD. Statistical analysis was performed with use of the Windows 97 MS Office (Excel Analysis toolpak) software. The 2 groups were compared with the 2-tailed Student t test and the χ 2 test for proportions. Paired data (at baseline and after treatment) were analyzed with the paired t test. A P value of <.05 was considered significant.
Results
A total of 17 patients on intravenous inotropic therapy (group 1) and 15 patients in class II/IIIa CHF (group 2) were titrated on carvedilol. There were 9 patients in class IIIb and 8 in class IV CHF at the start of milrinone therapy in group 1, whereas group 2 had 9 in class II and 6 in class IIIa CHF. The baseline clinical characteristics of patients in both groups are presented in Table I . As expected, patients in group 1 showed a trend toward a lower mean blood pressure (P < .34) and lower ejection fraction (P < .10) and had a significantly higher heart rate (P < .015). The two groups were well matched for age, sex, and heart failure therapy. The etiology of heart failure in the nonischemic patients in group 1 was as follows: hypertensive heart disease (3), alcoholic cardiomyopathy (3), valvular heart disease (2), and idiopathic cardiomyopathy (2) . Of the 6 patients with nonischemic cardiomyopathy in group 2, 3 had hypertensive heart disease, 2 had alcoholic cardiomyopathy, and 1 had peripartum cardiomyopathy.
The details of the titration phase of carvedilol are listed in Table II . Carvedilol was titrated successfully in 15 of 17 (88%) group 1 patients and 14 of 15 (93%) group 2 patients (P not significant [NS] ). The average titration period was 8.1 ± 1.8 weeks for group 1 compared with 6.7 ± 2.8 weeks for group 2 (P NS). The target dose was achieved in 13 of 15 (87%) group 1 patients and 14 of 14 group 2 patients (P NS).
Seven patients (47%) in group 1 had side effects during titration requiring a decrease in carvedilol dosage, slower titration, and increased frequency of inotropic therapy or extra diuretics. Three of these patients had hypotension, 2 had dizziness with orthostatic hypotension, and 2 had worsened CHF. Of the 2 patients who Table I . Baseline clinical characteristics of the patients in both groups (mean ± SD) failed titration, 1 was due to hypotension and worsening heart failure and 1 was referred for cardiac transplantation during the titration. Of the 4 patients (29%) in group 2 who had adverse effects during carvedilol titration, 2 had dizziness, 1 had hypotension, and 1 had second-degree atrioventricular block. Therapy was discontinued in 1 patient because of worsened CHF. During follow-up 8 of 15 (53%) group 1 patients were weaned off inotropic infusions in a mean of 8.4 ± 8.4 weeks. These patients have been off infusions for a mean duration of 18.6 ± 15.5 weeks. Of patients remaining on milrinone, there was a 50% decrease in the overall frequency of inotropic therapy. Although 1 patient in group 2 was hospitalized during titration, no patients in either group have had hospitalizations or emergency department visits for CHF during the follow-up period. Ten (63%) group 1 patients had improved by one or more functional classes at the end of the follow-up period. The functional class of group 1 patients had improved from a mean of 3.5 ± 0.5 before infusions to 2.6 ± 0.6 (P < .0005) after combined carvedilol/milrinone therapy.
Discussion
Patients in NYHA class IIIb/IV CHF who are treated with an inotropic infusion therapy have been excluded from most studies of β-blockers in heart failure in anticipation of further cardiac decompensation because of poor cardiac reserve and volume overload. The results of our study show that carvedilol titration can be achieved in a subset of patients with severe heart failure who were initially stabilized on intermittent milrinone infusions. We were able to titrate carvedilol in 88% of these patients, which is comparable to results obtained in less-symptomatic patients (NYHA class I-III) in earlier studies. 1, 4, 9 The better success rate in β-blocker titration in patients noted in our study could be attributed to the continued inotropic support provided by the milrinone therapy during the initiation phase of the β-blocker in these patients with advanced heart failure. This hypothesis needs to be evaluated in prospective trials because there are no data in this regard to date. The recent morbidity and mortality results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial 10 now demonstrate that patients with functional class III and IV CHF can benefit from β-blockade, making it imperative that we develop feasible ways to stabilize these patients for outpatient carvedilol titration.
Phosphodiesterase inhibitors, unlike dobutamine and dopamine, have been shown to demonstrate continued positive inotropic effects in patients on β-blockers, especially in a perioperative setting. [6] [7] [8] This has been attributed to the site of action of phosphodiesterase inhibitors in reducing the breakdown of cyclic adenosine monophosphate, being beyond the β-adrenergic receptor. 5 Hence phosphodiesterase inhibitors may be complementary to β-blockers, especially in the initial titration phase, when most of the adverse events are observed.
Previous studies have reported a 24% to 37% and 43% occurrence of nonfatal adverse events during carvedilol titration in patients in NYHA class I-III and class IV, respectively. 1, 4, 5, 9, 11 Our results are comparable in a more decompensated group of patients requiring inotropic support for stabilization. Worsening CHF was the predominant adverse event (22%) in patients with functional class IV. 4 In contrast, in our study only 2 patients (13%) had worsening CHF, suggesting a role of milrinone in alleviating the initial negative inotropic effect of β-blockade. However, 5 (33%) of these patients had dizziness or hypotension that could be due to vasodilation, a property shared by both the phosphodiesterase inhibitor and carvedilol.
Once the drug is initiated, patients on carvedilol show gradual improvement in their inotropic state and functional status as seen in prior studies of β-blockade in heart failure. [1] [2] [3] [4] [5] 9 Although 63% of our patients showed improvement in functional class with intermittent inotropic therapy and carvedilol titration, it is not know whether milrinone alone was responsible for the clinical improvement. It has been suggested that the most marked improvement after β-blockade occurs in patients with the most advanced heart failure. 12, 13 Our results demonstrate the feasibility of β-blockade in patients requiring milrinone therapy. Finally, 53% of the patients on carvedilol were successfully weaned off inotrope infusions, whereas all the others had decreased frequency of infusions. Strategies to wean patients off inotropic therapy, avoiding the long-term adverse effects, need to be developed. On the basis of our findings, using milrinone to stabilize patients with class IIIb/IV heart failure before and during β-blocker titration may be a reasonable strategy.
Limitations
This study was a retrospective nonrandomized clinical observation in a limited number of patients in class IIIb/IV CHF stabilized while on intermittent milrinone therapy. Safety and efficacy of either β-blockade or phosphodiesterase inhibitors are yet to be demonstrated in such patients, as is long-term clinical, survival, or hospitalization benefit. It is not known whether similar results could have been obtained without milrinone.
Conclusions
Patients with NYHA class IIIb/IV heart failure treated with inotropic therapy for recurrent decompensation or hospitalizations can be titrated on carvedilol, with similar success rates as in patients with NYHA class II/IIIa, after reaching a stable state while on milrinone and standard triple oral therapy. Most of these patients can be successfully weaned off milrinone infusions or have decreased frequency of infusions and demonstrate improved functional status after carvedilol titration. It is not known whether carvedilol assisted in the inotropic weaning or whether the β-blocker titration would have been successful without milrinone. Controlled studies of β-blocker titration with phosphodiesterase inhibitors need to be completed.
